Local
multiQure Begins Manufacturing Phase of MQ-201 Gene Therapy for First Huntington's Disease Patients - U.S.-Based Andelyn Biosciences Selected as Manufacturing Partner
A Roundtable is a way to meet new people and discuss this article in person at a local coffee shop or other venue.
Roundtables are designed for groups of four, with a shared subject and room for everyone to speak. Come for discussion, with no dating expectation.
Source: Barre Montpelier Times Argus

WARSAW, POLAND / ACCESS Newswire / November 19, 2026 / multiQure S.A. (WSE:MQR), a biotechnology company developing an RNAi gene therapy for Huntington's disease, is moving into the manufacturing phase of its MQ-201 therapy. The Company has selected Andelyn Biosciences…
This excerpt comes from the named source. Read the original for the full reporting.
Read the original at Barre Montpelier Times Argus


